Regulation of the Myocardial Endothelin System by Angiotensin-II and Losartan
| Autor: | Lorcan Sherry, Pauline E. McEwan, David J. Webb, Christopher J. Kenyon, Gillian A. Gray |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
Male
medicine.hormone medicine.medical_specialty Receptor expression Blood Pressure Losartan Endothelins Internal medicine medicine Animals RNA Messenger Protein Precursors Rats Wistar Receptor Aldosterone Pharmacology Angiotensin II receptor type 1 Endothelin-1 Receptors Endothelin Chemistry Angiotensin II Myocardium Receptor Endothelin B Endothelin 1 Rats Endocrinology Gene Expression Regulation Cardiology and Cardiovascular Medicine Endothelin receptor medicine.drug |
| Zdroj: | Journal of Cardiovascular Pharmacology. 36:S144-S147 |
| ISSN: | 0160-2446 |
| DOI: | 10.1097/00005344-200036051-00045 |
| Popis: | Evidence for interactions between the endothelin (ET) and renin-angiotensin systems is plentiful in vitro, but few studies have investigated these interactions in vivo. In the study reported here, we have investigated the influence of chronic angiotensin-II (A-II) infusion in vivo on expression of preproendothelin-1 (PPET-1) and endothelin-A-(ET A ) and endothelin-B-(ET B ) receptor mRNA in the heart. The role of the angiotensin type 1 (AT1)-receptor in mediating the actions of A-II was studied using losartan, the selective ATI-receptor antagonist. Male rats received an infusion of A-II (200 ng/kg/min) or vehicle for 14 days via mini-osmotic pumps; losartan (10 mg/kg/day) was administered in the drinking water. PPET- 1 and ET A - and ET B -receptor mRNA were detected in heart sections using nonradioactive antisense in situ hybridization. Independent treatments with either A-II or losartan had no significant effect on PPET-1, ET A - or ET B -receptor expression. Combined treatment resulted in an increase in PPET-1 mRNA (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|